Ed Arce
Stock Analyst at WestPark Capital
(3.80)
# 704
Out of 5,140 analysts
384
Total ratings
46.2%
Success rate
10.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $24 → $28 | $12.49 | +124.18% | 13 | Sep 30, 2025 | |
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $27.94 | +7.37% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $132 | $3.00 | +4,300.00% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $6.58 | +1,039.82% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $7.10 | +745.07% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $1.34 | +459.70% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $6.43 | +102.18% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $2.99 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $1.00 | +501.68% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $8.01 | +773.91% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $26.80 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $2.55 | +9,311.76% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.28 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $6.28 | +409.55% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $91.89 | -21.65% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $504.95 | -19.79% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $7.76 | -29.12% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $22.63 | +319.80% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $4.21 | +18.91% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $32.41 | +48.10% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $36.58 | -79.50% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.33 | +1,417.91% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $14.79 | -12.10% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $0.56 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $44.83 | -44.23% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.80 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $16.06 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $33.52 | -79.12% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $47.70 | -55.97% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.44 | - | 2 | Feb 15, 2017 |
Enanta Pharmaceuticals
Sep 30, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $12.49
Upside: +124.18%
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $27.94
Upside: +7.37%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $132
Current: $3.00
Upside: +4,300.00%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $6.58
Upside: +1,039.82%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $7.10
Upside: +745.07%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $1.34
Upside: +459.70%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $6.43
Upside: +102.18%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $2.99
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $1.00
Upside: +501.68%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $8.01
Upside: +773.91%
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $26.80
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $2.55
Upside: +9,311.76%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.28
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $6.28
Upside: +409.55%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $91.89
Upside: -21.65%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $504.95
Upside: -19.79%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $7.76
Upside: -29.12%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $22.63
Upside: +319.80%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $4.21
Upside: +18.91%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $32.41
Upside: +48.10%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $36.58
Upside: -79.50%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $0.33
Upside: +1,417.91%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $14.79
Upside: -12.10%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $0.56
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $44.83
Upside: -44.23%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.80
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $16.06
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $33.52
Upside: -79.12%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $47.70
Upside: -55.97%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.44
Upside: -